<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322606</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-137/CPH-001</org_study_id>
    <secondary_id>U1111-1162-5936</secondary_id>
    <nct_id>NCT02322606</nct_id>
  </id_info>
  <brief_title>A Phase 1, Single and Multiple Dose Study of TAK-137</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TAK-137 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability and pharmacokinetics of&#xD;
      TAK-137 in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1, randomized, placebo-controlled, double-blind, multiple ascending&#xD;
      dose study in Japanese healthy male participants to assess the safety, tolerability and PK&#xD;
      following single and multiple oral doses of TAK-137.&#xD;
&#xD;
      This study is composed of 2 parts, a Single Dose part (Cohorts 1 to 3) and a Multiple Dose&#xD;
      part (Cohorts 4 to 6). Up to 48 participants will be enrolled.&#xD;
&#xD;
      Single dose part (Cohorts 1-3): Single Dose, 3 dose levels, Placebo-Controlled, Randomized,&#xD;
      Double-Blind.&#xD;
&#xD;
      Each cohort will include 8 participants. Participants will be randomly assigned to either&#xD;
      TAK-137 or placebo treatment group within each cohort with an allocation ratio of 6:2.&#xD;
&#xD;
      The planned dose levels to be studied are 5, 10 and 20 mg. The principal investigator will&#xD;
      consult with the sponsor and the medical specialist as needed and will determine go/no-go for&#xD;
      the next cohort.. The dose in Cohorts 3 may be reduced to 2 mg/day instead of 20 mg/day if&#xD;
      the principal investigator, in consultation with the sponsor, considers it appropriate.&#xD;
&#xD;
      Multiple dose Part (Cohorts 4-6): Multiple Dose, 3 dose levels, Placebo-Controlled,&#xD;
      Randomized, Double-Blind.&#xD;
&#xD;
      Each cohort will include 8 participants. Participants will be randomly assigned to either&#xD;
      TAK-137 or placebo treatment group within each cohort with an allocation ratio of 6:2.&#xD;
&#xD;
      The planned dose levels to be studied are 5, 10,and 15 mg, however for Cohort 5 and 6, the&#xD;
      dose level may be amended based on the safety and tolerability data obtained from either&#xD;
      Cohorts 1-4 from this study or emerging data from the multiple rising dose study conducted,&#xD;
      in parallel in the United Sates (TAK-137_102). The principle investigator, in consultation&#xD;
      with the sponsor, will determine the dose levels for cohorts 5 and 6 (Not exceeding 20mg).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequencies of Adverse events (Single dose Part)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness, and causal relationship to TAK-137. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, reported from the first dose to the last dose of TAK-137.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequencies of Adverse events (Multiple dose Part)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness, and causal relationship to TAK-137. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, reported from the first dose to the last dose of TAK-137.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of changes from baseline for vital sign measurements at least once post-dose (Single dose Part)</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of changes from baseline for vital sign measurements at least once post-dose (Multiple dose Part)</measure>
    <time_frame>Up to 9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of changes from baseline for body weight measurements at least once post-dose (Single dose Part)</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of changes from baseline for body weight measurements at least once post-dose (Multiple dose Part)</measure>
    <time_frame>Up to 9 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with abnormal and clinically significant judged by investigator for electrocardiogram measurements at least once post-dose (Single dose Part)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The percentage of participants with abnormal and clinically significant judged by investigator, electrocardiogram measurements during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with abnormal and clinically significant judged by investigator for electrocardiogram measurements at least once post-dose (Multiple dose Part)</measure>
    <time_frame>Up to 9 days</time_frame>
    <description>The percentage of participants with abnormal and clinically significant judged by investigator, electrocardiogram measurements during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with significantly abnormal (epileptiform) judged by investigator for electroencephalogram measurements at least once post-dose (Single dose Part)</measure>
    <time_frame>Up to 1 day</time_frame>
    <description>The percentage of participants with significantly abnormal (epileptiform) judged by investigator, electroencephalogram measurements during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with significantly abnormal (epileptiform) judged by investigator for electroencephalogram measurements at least once post-dose (Multiple dose Part)</measure>
    <time_frame>Up to 7 days</time_frame>
    <description>The percentage of participants with significantly abnormal (epileptiform) judged by investigator, electroencephalogram measurements during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who meet the markedly abnormal criteria for safety laboratory tests at least once post-dose (Single dose Part)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>The percentage of participants with any markedly abnormal, standard safety laboratory values, including hematology and serum chemistries during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who meet the markedly abnormal criteria for safety laboratory tests at least once post-dose (Multiple dose Part)</measure>
    <time_frame>Up to 9 days</time_frame>
    <description>The percentage of participants with any markedly abnorma, standard safety laboratory values, including hematology and serum chemistries during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of observed value for Stimulant relapse risk scale (excerpt) (Single dose Part)</measure>
    <time_frame>Up to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of observed value for Stimulant relapse risk scale (excerpt) (Multiple dose Part )</measure>
    <time_frame>Up to 9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of pharmacokinetic parameters (AUC(0-168), AUC(0-tlqc), Cmax, Tmax, AUC(0-inf), T1/2, CL/F, Vz/F and MR) for unchanged TAK-137 and its metabolite M-I in plasma (Single dose Part)</measure>
    <time_frame>Days 1-8</time_frame>
    <description>The pharmacokinetic parameters (AUC(0-168), AUC(0-tlqc), Cmax, Tmax, AUC(0-inf), T1/2, CL/F, Vz/F and MR) will be estimated from a Non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive statistics (mean, SD, median, min. and max.) of pharmacokinetic parameters for unchanged TAK-137 and its metabolite M-I in plasma (Multiple dose Part)</measure>
    <time_frame>Days 1-9</time_frame>
    <description>The pharmacokinetic parameters (AUC(0-24), AUC(0-tlqc), Cmax, Tmax, AUC(0-inf), T1/2, CL/F, Vz/F, MR, Cavg, R(AUC), R(Cmax), AI(AUC) and AI(T1/2)) will be estimated from a Non-compartmental analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive statistics (mean, SD, median, minimum and maximum) of pharmacokinetic parameters (Fe and CLr) for unchanged TAK-137 and its metabolite M-I in urine (Single dose Part)</measure>
    <time_frame>Days 1-4 (Prior to administration and 0-24, 24-48, 48-72 hours after administration)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Japanese Adult Male</condition>
  <arm_group>
    <arm_group_label>Cohort 1: TAK-137 5 mg, TAK-137 placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-dose administration in a fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-dose administration in a fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single-dose administration in a fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: TAK-137 5mg, TAK-137 placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Once daily for 7 days in a fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: TAK-137 10 mg, TAK-137 placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Once daily for 7 days in a fasting state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: TAK-137 15 mg, TAK-137 placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Once daily for 7 days in a fasting state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137 5 mg tablet, TAK-137 placebo tablet</intervention_name>
    <arm_group_label>Cohort 1: TAK-137 5 mg, TAK-137 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137 5 mg tablet, TAK-137 placebo tablet</intervention_name>
    <arm_group_label>Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet</intervention_name>
    <arm_group_label>Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137 5mg tablet, TAK-137 placebo tablet</intervention_name>
    <arm_group_label>Cohort 4: TAK-137 5mg, TAK-137 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137 5 mg tablet, TAK-137 placebo tablet</intervention_name>
    <arm_group_label>Cohort 5: TAK-137 10 mg, TAK-137 placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-137 5mg tablet, TAK-137 placebo tablet</intervention_name>
    <arm_group_label>Cohort 6: TAK-137 15 mg, TAK-137 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant eligibility is determined according to the following criteria prior to&#xD;
             entry into the study:&#xD;
&#xD;
               -  In the opinion of the investigator, the participant is capable of understanding&#xD;
                  and complying with protocol requirements.&#xD;
&#xD;
               -  The participant signs and dates a written, ICF and any required privacy&#xD;
                  authorization prior to the initiation of any study procedures.&#xD;
&#xD;
               -  The participant is a healthy Japanese adult male volunteer.&#xD;
&#xD;
               -  The participant is between 20 and 45 years of age at the time of informed&#xD;
                  consent.&#xD;
&#xD;
               -  The participant has a body weight of at least 50 kg and has a body mass index&#xD;
                  (BMI) between 18.5 and 24.9 kg/m2 at the time of screening and baseline (Day -1).&#xD;
&#xD;
               -  A male participant who is sexually active with a female partner of childbearing&#xD;
                  potential agrees to use adequate contraception after signing the ICF for up to 12&#xD;
                  weeks from the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any participant who meets any of the following criteria will not qualify for entry&#xD;
             into the study:&#xD;
&#xD;
               -  The participant has received any investigational drugs within 30 days prior to&#xD;
                  the first study drug administration.&#xD;
&#xD;
               -  The participant has received TAK-137 in a previous clinical study.&#xD;
&#xD;
               -  The participant is an immediate family member, study site employee, or is in a&#xD;
                  dependant relationship with a study site employee who is involved in the conduct&#xD;
                  of this study (eg, spouse, parent, child, sibling) or may consent under duress.&#xD;
&#xD;
               -  The participant has uncontrolled, clinically significant neurologic,&#xD;
                  cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic&#xD;
                  or endocrine disease or other abnormality which may impact the ability of the&#xD;
                  participant to participate or potentially confound the study results.&#xD;
&#xD;
               -  The participant has previously had a seizure or convulsion (lifetime), including&#xD;
                  absence seizure and febrile convulsion&#xD;
&#xD;
               -  The participant has a history of psychiatric disorders.&#xD;
&#xD;
               -  The participant has a known hypersensitivity to medication(s) or food(s).&#xD;
&#xD;
               -  The participant has positive results in the urine drug screening test at&#xD;
                  screening.&#xD;
&#xD;
               -  The participant has a history of drug abuse (defined as any illicit drug use) or&#xD;
                  a history of alcohol abuse within 2 years prior to the screening or is unwilling&#xD;
                  to agree to abstain from alcohol and drugs throughout the study period.&#xD;
&#xD;
               -  The participant has taken any excluded medication, supplements, or food products&#xD;
                  listed in the Excluded Medications and Dietary Products during the screening&#xD;
                  period, or requires such medication or food during the study.&#xD;
&#xD;
               -  The participant intends to donate sperm from the signing of ICF to 12 weeks after&#xD;
                  the last dose.&#xD;
&#xD;
               -  The participant has current or recent (within 6 months) gastrointestinal disease&#xD;
                  that would be expected to influence the absorption of drugs (i.e., a history of&#xD;
                  malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis,&#xD;
                  frequent [more than once per week] occurrence of heartburn, or any surgical&#xD;
                  intervention, [e.g. gastrectomy, cholecystectomy, etc.]).&#xD;
&#xD;
               -  The subject has a history of cancer.&#xD;
&#xD;
               -  The subject has a positive test result for hepatitis B surface antigen (HBsAg),&#xD;
                  hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV)&#xD;
                  antibody/antigen, or serological reactions for syphilis at screening.&#xD;
&#xD;
               -  The subject has poor peripheral venous access.&#xD;
&#xD;
               -  The subject has undergone whole blood collection of at least 200 mL within 4&#xD;
                  weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the first&#xD;
                  study drug administration.&#xD;
&#xD;
               -  The participant has undergone whole blood collection of at least 800 mL in total&#xD;
                  within 52 weeks (364 days) prior to the first study drug administration.&#xD;
&#xD;
               -  The participant has undergone blood component collection within 2 weeks (14 days)&#xD;
                  prior to the first study drug administration.&#xD;
&#xD;
               -  The participant has any clinically significant ECG abnormality at time of&#xD;
                  screening or baseline (Day -1).&#xD;
&#xD;
               -  The participant has abnormal screening or baseline (Day -1) laboratory values&#xD;
                  that suggest a clinically significant underlying disease, or the participant has&#xD;
                  the following lab abnormalities: alanine aminotransferase (ALT) and/or aspartate&#xD;
                  aminotransferase (AST) &gt;1.5 Ã— the upper limits of normal (ULN).&#xD;
&#xD;
               -  The participant has an abnormal EEG during screening&#xD;
&#xD;
               -  The participant is at risk for suicide based on the investigator's determination.&#xD;
&#xD;
               -  The participant who, in the opinion of the investigator, is unlikely to comply&#xD;
                  with the protocol or is unsuitable for any other reason.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>October 28, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

